Home> Announcements> International topics> Trilateral Cooperation (JPO-EPO-USPTO)> Trilateral Project 24.1-Biotechnology> Trilateral Project 24.1-Biotechnology 090
Main content starts here.
If the entire polypeptide sequence is disclosed, that should enable claims drawn to any antigenic determinant of at least eight contiguous amino acid as described in the example.
This is dependent upon what "biological activity" is claimed. Analysis of an "epitope of antigen" is particularly fact-dependent.